Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors. Academic Article uri icon


  • Proteasome inhibitors (e.g., bortezomib, MG132) are known to enhance adeno-associated virus (AAV) transduction; however, whether this results from pleotropic proteasome inhibition or off-target serine and/or cysteine protease inhibition remains unresolved. Here, we examined recombinant AAV (rAAV) effects of a new proteasome inhibitor, carfilzomib, which specifically inhibits chymotrypsin-like proteasome activity and no other proteases. We determined that proteasome inhibitors act on rAAV through proteasome inhibition and not serine or cysteine protease inhibition, likely through positive changes late in transduction.

published proceedings

  • J Virol

altmetric score

  • 3

author list (cited authors)

  • Mitchell, A. M., & Samulski, R. J

citation count

  • 34

complete list of authors

  • Mitchell, Angela M||Samulski, R Jude

publication date

  • December 2013